These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34865342)

  • 1. [Optimal timing significance and clinical implications for the treatment of chronic HBV-infected patients with normal ALT].
    Fan YX; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2020 Dec; 28(12):985-987. PubMed ID: 34865342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues.
    Jang TY; Wei YJ; Yeh ML; Liu SF; Hsu CT; Hsu PY; Liu TW; Lin YH; Liang PC; Hsieh MH; Ko YM; Tsai YS; Chen KY; Lin CC; Tsai PC; Wang SC; Huang CI; Lin ZY; Chen SC; Chuang WL; Huang JF; Dai CY; Huang CF; Yu ML
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):303-310. PubMed ID: 33109431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The comparison of liver inflammation and fibrosis between chronic HBV and HCV infection].
    Wang L; Fan YX; Ding Y; Sheng QJ; Zhang C; Zhao LR; Xia TT; An ZY; Bai H; Shi HY; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2017 Jun; 25(6):419-423. PubMed ID: 28763858
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Alanine aminotransferase normalization with antiviral therapies in hepatitis B].
    Yang DL
    Zhonghua Gan Zang Bing Za Zhi; 2019 Oct; 27(10):741-747. PubMed ID: 31734986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
    Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Optimal timing of antiviral therapy for chronic HBV-infected patients with normal ALT].
    Gui HL; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2020 Dec; 28(12):988-991. PubMed ID: 34865343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase.
    Zhao Q; Liu K; Zhu X; Yan L; Ding Y; Xu Y; Lou S; Zhao G; Xie Q; Gao Y; Bao S; Wang H
    Antiviral Res; 2020 Dec; 184():104953. PubMed ID: 33065138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
    Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
    J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination.
    Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1842-8. PubMed ID: 23829381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of liver histological changes and a sustained virological response to peginterferon among chronic hepatitis B e antigen-positive patients with normal or minimally elevated alanine aminotransferase levels.
    Chen J; Xu CR; Xi M; Hu WW; Tang ZH; Zang GQ
    J Viral Hepat; 2017 Jul; 24(7):573-579. PubMed ID: 28107601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
    Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
    Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels.
    Yan JY; Li ZQ; Yu ZJ; Kan QC
    J Cell Biochem; 2019 Apr; 120(4):6632-6641. PubMed ID: 30368885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NIH consensus development statement on management of hepatitis B.
    Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
    NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Risk factors associated with the progression of chronic HBV infection in patients with normal ALT].
    Wei L; Li H; Hu P
    Zhonghua Gan Zang Bing Za Zhi; 2020 Dec; 28(12):995-998. PubMed ID: 34865345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and treatment of chronic hepatitis B: an update.
    Morgan M; Park W; Keeffe EB
    Minerva Gastroenterol Dietol; 2007 Mar; 53(1):25-41. PubMed ID: 17415343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points.
    Lai CL; Yuen MF
    Ann Intern Med; 2007 Jul; 147(1):58-61. PubMed ID: 17606962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two patterns of alanine aminotransferase increase to predict long-term viral response in chronic hepatitis B patients: virus- or host-induced?
    You H; Wu X; Ou X; Ma H; Wang Q; Liu T; Cong M; Wang P; Wang B; Jia J
    Antivir Ther; 2011; 16(3):299-307. PubMed ID: 21555812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HBV: Do I treat my immunotolerant patients?
    Vlachogiannakos J; Papatheodoridis GV
    Liver Int; 2016 Jan; 36 Suppl 1():93-9. PubMed ID: 26725904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients.
    Jeng WJ; Sheen IS; Chen YC; Hsu CW; Chien RN; Chu CM; Liaw YF
    Hepatology; 2013 Dec; 58(6):1888-96. PubMed ID: 23744454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.